Want to see IVVD full AI Analyst Report?
IVVD Stock Chart & Stats
$1.74
-$0.05(-9.00%)
At close: 4:00 PM EST
$1.74
-$0.05(-9.00%)
Day’s Range― - ―
52-Week Range$0.48 - $3.07
Previous CloseN/A
Volume606.77K
Average Volume (3M)5.72M
Market Cap
$218.75M
Enterprise Value$227.04
Total Cash (Recent Filing)$184.15M
Total Debt (Recent Filing)$8.63M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Aug 19, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding294,607,450
10 Day Avg. Volume3,255,297
30 Day Avg. Volume5,723,030
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.76
Price to Sales (P/S)7.96
P/FCF Ratio-7.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside474.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$67.29M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA ~93% gross margin signals durable unit economics for PEMGARDA and related antibody products. High product-level margin supports scalable profitability as revenues grow, cushions R&D and commercialization spend, and gives pricing flexibility for long-term market penetration among immunocompromised patients.
Low Financial LeverageVery low debt relative to equity reduces refinancing and interest-rate pressure, providing financial flexibility to fund pivotal trials and commercialization. This balance sheet strength extends the runway versus cash burn and supports less dilutive financing options over the medium term.
Commercial Momentum And Pipeline ProgressPEMGARDA's sustained commercial growth, resumed upsized pivotal enrollment, and confirmed neutralization against recent variants reflect durable demand and scientific relevance. Combined with VYD2311 progress and operational simplifications, this strengthens long-term revenue trajectory and regulatory positioning if efficacy holds.
Bears Say
High Cash BurnMaterial negative operating and free cash flow mean the business consumes cash to fund trials and commercialization. Despite improvement versus prior years, ongoing burn requires external financing or rapid revenue scaling, constraining strategic optionality and raising dilution risk over the next several quarters.
Sustained Operating LossesLarge, persistent operating and net losses show the company is not yet generating operating profits. Negative returns on capital make internal funding of growth unlikely, increase reliance on external capital, and heighten execution risk around achieving breakeven as new product spend continues.
Regulatory Transition RiskThe planned end of the COVID EUA creates a structural deadline to secure full biologics approval. This procedural uncertainty could affect access, reimbursement, and prescribing patterns if a BLA or label changes are delayed, making longer-term revenue contingent on successful regulatory outcomes.
Invivyd News
IVVD FAQ
What was Invivyd’s price range in the past 12 months?
Invivyd lowest stock price was $0.48 and its highest was $3.07 in the past 12 months.
What is Invivyd’s market cap?
Invivyd’s market cap is $218.75M.
When is Invivyd’s upcoming earnings report date?
Invivyd’s upcoming earnings report date is Aug 19, 2026 which is in 31 days.
How were Invivyd’s earnings last quarter?
Invivyd released its earnings results on May 14, 2026. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.073 by -$0.057.
Is Invivyd overvalued?
According to Wall Street analysts Invivyd’s price is currently Undervalued.
Does Invivyd pay dividends?
Invivyd does not currently pay dividends.
What is Invivyd’s EPS estimate?
Invivyd’s EPS estimate is -0.11.
How many shares outstanding does Invivyd have?
Invivyd has 294,607,450 shares outstanding.
What happened to Invivyd’s price movement after its last earnings report?
Invivyd reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.073. Following the earnings report the stock price went down -21.088%.
Which hedge fund is a major shareholder of Invivyd?
Currently, no hedge funds are holding shares in IVVD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invivyd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (474.71% Upside)
$10.00 (474.71% Upside)
Blogger Sentiment
Neutral
IVVD Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 22.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.91%
12-Months-Change
Fundamentals
Return on Equity
-53.48%
Trailing 12-Months
Asset Growth
133.02%
Trailing 12-Months
Company Description
Invivyd
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
IVVD Stock 12 Month Forecast
Average Price Target
$10.00
▲(474.71% Upside)
Technical Analysis
Larimar Therapeutics
―
Rocket Pharmaceuticals
―
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
9.49% Insiders
7.58% Mutual Funds
45.05% Other Institutional Investors
30.21% Public Companies and Individual Investors